Xeomin: adverse event reports filed with FDA

5,438

reports as suspect product

0% of all reports · about 305 a year

637

reports, 12 months to June 2026

760 in the 12 months before

12.2%

marked serious by the reporter

20.1% across the class

1.7%

record death among outcomes, as reported

92 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Xeomin reports recording the termmedian drug in acetylcholine release inhibitor

1. Drug ineffectivethe medicine did not work as expected33.2%1,803
2. Off label useused for a purpose or in a way not on the label21.6%1,177
3. Therapeutic response decreasedthe medicine worked less well13.4%728
4. Injection site painpain where the injection was given6.1%329
5. Product preparation issuea problem preparing the product3.8%206
6. Injection site swellingswelling where the injection was given3.7%201
7. Overdosea dose above the recommended amount3.7%200
8. Headachehead pain3.3%182
9. Product use in unapproved indicationused for a purpose not on the label3.1%166
10. Painpain, site not specified2.9%156
11. Injection site mass2.4%129
12. Injection site erythemaredness where the injection was given2.4%128
13. Eyelid ptosis2.3%126
14. Dysphagiadifficulty swallowing2%107
15. Incorrect route of product administrationthe product was given by the wrong route2%107
16. Burning sensationa burning feeling1.9%101
17. Swellingswelling1.7%91
18. Erythemaskin redness1.6%88
19. Dizzinesslight-headedness or unsteadiness1.5%83
20. Underdoseless than the intended dose1.5%83
21. Nauseafeeling sick1.4%75
22. Dyspnoeashortness of breath1.3%71
23. Vision blurredblurred vision1.3%71
24. Fatiguetiredness1.2%67
25. Paraesthesiatingling or pins and needles1.2%67
26. Deaththe patient died; cause not stated by this term1.2%66
27. Muscular weaknessmuscle weakness1.2%65
28. Hypersensitivityan allergic-type reaction1.1%60
29. Rashskin rash1.1%58
30. Influenza like illnessflu-like symptoms1%57

Top 30 of 358 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 6 drugs in the acetylcholine release inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 88,564 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 92.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 5,438 reports.

Drugs most often listed in the same reports

Other products listed in reports where Xeomin is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the acetylcholine release inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Xeomin as a suspect or interacting product; reports listing it only as a concomitant medication (182) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.